Alexander Ambinder is an Oncology physician affiliated with Johns Hopkins University. OpenAlex indexes 95 publications with 753 citations (h-index 14); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1650 Orleans St # 1186
Baltimore, MD 212870013
Telephone
410-614-4459Provider last certified this registry record 16 Mar 2026.
Clinical trials
- Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SERVIER PHARMACEUTICALS LLCProgram year202521 payments$11,950openpaymentsdata.cms.gov ↗
- Melinta Therapeutics, LLCProgram year20251 payment
- Daiichi Sankyo Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
38.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor21.3%Valacyclovir100%Part D≥24 patientsFluoroquinolone Antibacterial10.9%Moxifloxacin Hcl52%Levofloxacin48%Part D<11 patients+ 1 more class in this area
Cancer & immunology
27.3%BCL-2 Inhibitor9%Venclexta100%Part D<11 patientsIsocitrate Dehydrogenase 1 Inhibitor5.6%Tibsovo100%Part D<11 patients+ 3 more classes in this area
Cardiovascular
15.4%Calcium channel blocker6%Amlodipine Besylate100%Part D<11 patientsThiazide diuretic4.9%Hydrochlorothiazide100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Roger Blumenthal, MD
Johns Hopkins University
Erin Michos, MD
Johns Hopkins University
Morgan Grams, MD
Johns Hopkins University
Mario Eisenberger, MD
Johns Hopkins University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”